Full Press Release Details
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide in Patients as Young as 2 years old.
RYTM
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide in Patients as Young as 2 years old
Key Takeaway: Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide in Patients as Young as 2 years old